CM/PHR/23/5702 - NHS National Framework for Tocilizumab - March 2024

A Contract Award Notice
by 02182135

Source
Contracts Finder
Type
Framework (Products)
Duration
1 year
Value
£47M
Sector
HEALTH
Published
08 Apr 2024
Delivery
01 Mar 2024 to 28 Feb 2025
Deadline
03 Jan 2024 13:00

Concepts

Location

Geochart for 1 buyers and 2 suppliers

1 buyer

2 suppliers

Description

Project Title: NHS National Framework for Tocilizumab - March 2024 Offer reference number: CM/PHR/23/5702 CM/PHR/23/5702/01 NHS Framework for Tocilizumab LONDON and SOUTH OF ENGLAND. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/23/5702/02 NHS Framework for Tocilizumab NORTH OF ENGLAND and MIDLANDS AND EAST. Period of framework: 1 March 2024 to 28 February 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.

Award Detail

1 Roche Products (Welwyn Garden City)
  • Value: £46,600,000
2 Fresenius Kabi (Runcorn)
  • Value: £46,600,000

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

PARTIES APPOINTED TO THE FRAMEWORK AGREEMENT CM-PHR-23-5702 Tocilizumab PARTIES APPOINTED TO THE FRAMEWORK AGREEMENT CM-PHR-23-5702 Tocilizumab.docx Document No. 03 - Framework Agreement and Terms and Conditions Document No. 03 - Framework Agreement and Terms and Conditions.pdf Document No.10 - Pharmacy Purchasing Points CM-PHR-23-5702 Document No.10 - Pharmacy Purchasing Points CM-PHR-23-5702.xlsx Transparency Award Schedule - CM_PHR_23_5702 Transparency Award Schedule - CM_PHR_23_5702.pdf 231129 - FTS 2023S 000-035227 - NHS National Framework for Tocilizumab - March 2024 - Find a Tender 231129 - FTS 2023S 000-035227 - NHS National Framework for Tocilizumab - March 2024 - Find a Tender.pdf

Reference

Domains